Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Single-arm Study to Evaluate the Safety, Tolerability, Efficacy of RC108 in Combination With Furmonertinib and Toripalimab in Patients With Advanced EGFR-mutated NSCLC Ib/II Study

NCT05821933 is registered in ClinicalTrials.gov with RemeGen Co., Ltd. as lead sponsor.

NCT NCT05821933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05821933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Single-arm Study to Evaluate the Safety, Tolerability, Efficacy of RC108 in Combination With Furmonertinib and Toripalimab in Patients With Advanced EGFR-mutated NSCLC Ib/II Study
Lead sponsor
RemeGen Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 7, 2023
Completion date
September 1, 2026
Enrollment
106 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc